Navigation Links
Cell Therapeutics Announces Receipt of NASDAQ Listing Update
Date:3/6/2009

"http://www.celltherapeutics.com" target="_new">www.celltherapeutics.com.

This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results. These risks and uncertainties include, without limitation, the Company's ability to achieve compliance with the NASDAQ Capital Market's continued listing requirements by April 6, 2009, including the market value of listed securities requirement, as well as other risks and uncertainties that could affect the Company's business operations and the development of the Company's products including the Company's need to raise additional capital, risks associated with preclinical and clinical developments in the biopharmaceutical industry in general including, without limitation, the potential failure of a product to prove safe and effective for treatment of a specific condition, determinations by regulatory, patent and administrative governmental authorities, competitive factors, technological developments, and costs of developing, producing and selling the product(s). You should also review the risk factors listed or described from time to time in CTI's filings with the Securities and Exchange Commission including, without limitation, CTI's most recent filings on Forms 10-K, 8-K, and 10-Q. Except as may be required by law, CTI does not intend to update or alter its forward-looking statements whether as a result of new information, future events, or otherwise.

    Media Contact:
    Dan Eramian
    T: 206.272.4343
    C: 206.854.1200
    E: media@ctiseattle.com
    www.CellTherapeutics.com/press_room

    Investors Contact:
    Ed Bell
    T: 206.272.4345
    Lindsey Jesch Logan
    T: 206.272.4347
    F: 206.272.4434
    E: invest@ctiseattle.com
    www.CellTherapeutic
'/>"/>
SOURCE  Cell Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 

Related biology technology :

1. Proteon Therapeutics Completes $38M Equity Financing; Initiates Phase 1/2 Clinical Study of PRT-201 in Hemodialysis Patients and Signs Option Agreement With Major Pharmaceutical Company
2. Pharmexa and Affitech to Combine Operations to Create a New Antibody Therapeutics Company
3. ExonHit Therapeutics Invested Strongly in 2008 for Pivotal 2009 Results
4. Pearl Therapeutics Appoints Perry Karsen as Chief Executive Officer
5. CV Therapeutics Advises Stockholders to Take No Action at This Time in Response to Astellas Tender Offer
6. Cornerstone Therapeutics to Host Quarter and Year Ended December 31, 2008 Conference Call
7. BN ImmunoTherapeutics Reports Further Data on PROSTVAC(TM)
8. Nektar Therapeutics Reports Fourth Quarter and Year-End 2008 Financial Results
9. Synvista Therapeutics Announces Restructuring of Dividend Obligation to Preferred Stockholders and Decision to Delist from NYSE Alternext and Terminate SEC Registration of Common Stock
10. Pearl Therapeutics Secures $8 Million in Debt Financing
11. Amsterdam Molecular Therapeutics Reports Full Year Results 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)...  regulated information — Global biopharmaceutical company UCB, Inc. ... the launch of a new Pledge campaign for people ... Pledge empowers the millions of Americans living ... personal commitment to demand more: greater understanding of the ... additional partial-onset seizure control.  More information is available at ...
(Date:6/18/2013)... The "Bioinformatics Market By Sector (Molecular Medicine, ... & Data Analysis Services) & Application (Genomics, Proteomics & Drug ... Drivers, Restraints, and Opportunities in North America ... and Rest of World. Browse ... 22 Figures 364 Pages and an ...
(Date:6/18/2013)... This webinar will examine the history ... and review the basic FDA regulations and guiding ... these principles through real world case studies and ... on FDA regulations and guidance related to prescription ... traditional and newer forms of promotional materials for ...
(Date:6/18/2013)... , June 18, 2013   Lexicon ... a biopharmaceutical company focused on discovering breakthrough treatments ... Northcott has joined the company as its ... Mr. Northcott brings extensive commercial experience to Lexicon, ... a variety of therapeutic areas. Mr. ...
Breaking Biology Technology:Professional Golfer Jeff Klauk Tees Off New Pledge Campaign for People Living with Epilepsy 2Professional Golfer Jeff Klauk Tees Off New Pledge Campaign for People Living with Epilepsy 3Professional Golfer Jeff Klauk Tees Off New Pledge Campaign for People Living with Epilepsy 4Professional Golfer Jeff Klauk Tees Off New Pledge Campaign for People Living with Epilepsy 5Professional Golfer Jeff Klauk Tees Off New Pledge Campaign for People Living with Epilepsy 6Bioinformatics Market Worth $7.5 Billion by 2017 2Bioinformatics Market Worth $7.5 Billion by 2017 3Drug Advertising and Promotion Labeling: FDA Regulations, New Webinar Hosted by Xtalks 2John Northcott Joins Lexicon as Vice President of Marketing, Commercial Strategy and Operations 2John Northcott Joins Lexicon as Vice President of Marketing, Commercial Strategy and Operations 3
... 25 Celator Pharmaceuticals today announced that Scott Jackson, chief ... Piper Jaffray Health Care Conference in New York and the ... provide a corporate overview and an update on the company,s ... follows: , , ...
... 25 AngioGenex, Inc. (OTC Bulletin Board: AGGX) is a ... and proteins for the discovery and development of anti-angiogenic drugs ... 2008 objectives and its key business goals for 2009. , ... of important milestones that it set for itself in 2008. ...
... today announced that data from its phase 1/2 clinical ... highlighted in an oral presentation at the 50th Annual ... San Francisco, California, on December 9, 2008. , ... the XIAP Antisense Oligonucleotide (AEG35156) in Combination with Idarubicin ...
Cached Biology Technology:Celator(R) Pharmaceuticals to Present at Piper Jaffray Health Care Conference and Mid-Atlantic Capital Conference 2AngioGenex Reviews 2008 Achievements and Sets Goals for 2009 2AngioGenex Reviews 2008 Achievements and Sets Goals for 2009 3Aegera Therapeutics' phase 1/2 clinical trial results selected for oral presentation at 2008 ASH Annual Meeting 2Aegera Therapeutics' phase 1/2 clinical trial results selected for oral presentation at 2008 ASH Annual Meeting 3
(Date:6/17/2013)... the concept of improving original foundations with more modern ... University of Pittsburgh,s Kenneth P. Dietrich School of Arts ... could make drug delivery, gas storage, and gas transport ... were reported in the latest issue of the ... ). , The recent work builds upon Pitt Associate ...
(Date:6/17/2013)... SAN FRANCISCO-- Vitamin D supplementation may help delay early ... finds. The results were presented Monday at The Endocrine ... girls, puberty generally begins between the ages of 10 ... 12 to 16 years of age. Precocious puberty is ... age of 8; in boys, it is diagnosed when ...
(Date:6/17/2013)... State University research associate has received a prestigious fellowship ... prevent the spread of malaria. , Bart Bryant, research ... Health,s National Research Service Award Individual Postdoctoral Fellowship, which ... Kansas State University researcher to receive the award and ... such an award. , Bryant, a university doctoral graduate ...
Breaking Biology News(10 mins):'Chemical architects' build materials with potential applications in drug delivery and gas storage 2Vitamin D supplementation may delay precocious puberty in girls 2NIH fellowship helps researcher fight malaria, understand mosquito immunity 2
... DALLAS May 11, 2010 Microbiologists at UT Southwestern ... a potential target in cattle that could be exploited to ... strain of Escherichia coli . In the ... Proceedings of the National Academy of Sciences , researchers ...
... is not the only vehicle that can be propelled electrically. ... Mikel Lejarza, Jose Ignacio Uriarte, Miguel ngel Gmez Solaetxe and ... on an innovative project: to have a sailing boat that ... electric energy obtained from the movement of the wind in ...
... 2010) -- Cell-cell junctions are multi-molecular complexes that ... as barriers to permeability, and allow intercellular transport. ... Spring Harbor Laboratory Press, surveys current research on cell ... University) and W. James Nelson (Stanford University), both leaders ...
Cached Biology News:UT Southwestern researchers find mechanism that may stop E. coli from developing in cattle 2Project for sailing vessels to maneuver in ports using electric energy from wind 2Project for sailing vessels to maneuver in ports using electric energy from wind 3
This CLS number is a new product number, created to easily match Cornings product number. If showing no availability yet, please order under the old Sigma-Aldrich number (E6027) or contact customer s...
... samples may be carried out using this high ... System control and data processing is provided by ... elegant, powerful and very easy to use software ... 2000., The supplied detector is the ground breaking ...
Narrow-mouth has heavy-duty rim. Approximate graduations are in durable white enamel. Extra large marking space. capacity 125 mL Special grade: student grade...
... to MSY2/YBOX2 ( Abpromise for ... Antigen: Synthetic peptide derived from ... of human YBX2. (Note: the ... Entrez ...
Biology Products: